it's up almost 100% since Dec. and still gaining traction. Gern is down by 21%. Other than SP gains what does MEIP have that GERN is missing? 84% institutional ownership. Small float. Adequate cash(%$75mil), potential approval under Norvartis ext. comb label and a new FDA approval system. Several pipeline drugs. A much larger market in AML & MDS. A management team that delivers in a timely manner. Makes one want to start questioning one's religion.
they obviously know something you don't know jkokao with all your pumping. I'm beginning to think you are a contrarian indicator....the more you pump here the more the SP remains flat eventually allowing for a MM bear raid. $2.42 gap fill is looking mighty tasty right now. Scarlet will see to it next week as with all his previous CC. How will this one differ? He already said Phase II MF expansion will happen in the summer. I can't see any catalyst till then. The company has had plenty of time to deliver AML data...since the FDA hold lift last fall. Everyone said Teferri was busy with that and had no time to address the data update. 5 months later what's the excuse now? Are they keeping it from the investment community? That's material info. We are now sitting at the partial hold lift SP of $3.05 last June. The full hold lift in Nov. hardly moved the SP($2.80). Your J&J partnership has run out of steam in supporting GERN's SP and has given back all it's gains. The next step is in Janssen's pocket & they don't seem that pumped by this deal, otherwise they would be promoting it themselves. Gern's management has been relegated to changing oil in porches sitting in the Menlo Park parking lot. It's an esoteric market niche right now. I'm from Hodge Podge Pond on the Missouri, now show me the money. I have only half of mine left after losing it here.
check the 8K potty training filing Hairy
"With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Janssen is effective as of December 15, 2014 and the $35 million initial payment under the collaboration agreement is due to the company.
Additional details regarding the collaboration can be found in Geron`s Form 8-K filed with the Securities and Exchange Commission on November 13/2014"
they added 400,000 this morning as yesterday's close was 5.3 million avail. and today 4.9 SP has remained static so it's a rotational game with them. Close to 25mil total currently.
Net overall institutional ownership 42% down 8.42% from 50.42% last quarter.
Symmetrical triangles form with lower highs and higher lows. Because of their shape, they can act as either a continuation or a reversal pattern. This will be signaled by the breakout. An upward breakout is a bullish signal, while a downward breakout is bearish.
5.3 mil short positions available....means total number has fallen below 25mil to 24.7
Biopearl so what are you saying? Authenticity of data trial end points depends on semantics? If MEIP was playing fast and loose with CR & PR definitions then Scarlet is playing slow and tight lipped. We are approx. a year behind schedule with MF phase II expansion trials. The caveat everyone is eluding to here, namely fast track designation(BAT) has dragged on without any straight answers from Scarlet. Last month's convention in NYC btwn investors and CEO , NOT ONE POTENTIAL INVESTORS ASKED SCARLET ANY QUESTIONS...WHY? These aren't small fry yahoo board investors....this is Wall Street. He has gone on record at every CC previously from last year in January saying GERN was not pursuing fast track for IMET. Last year in January's J.P. Morgan conference he seemed to still be perplexed as to understanding IMET's mechanism of action in order to establish endpoints for trials going forward. "It's a mystery" Maybe the FDA just slapped the hold on cause they thought GERONIMO wasn't really that serious about seeking approval. The hold may have forced their hand in the matter but Jannsen doesn't appear too rushed either.
MEIP for what their current worth ($5-$6/share) has targeted a much wider spectrum of possible cures in the AML & MDS space, plus they have a pieline. This means potential earnings if they are successful as it appears they will and even in INCY's case even if they are not so successful but have a symptomatic treatment. With all of GERN's cure for cancer rhetoric the SP just sits. Eventually even beliebers have to deal with reality. MF alone is too small a target to set GERN up as a commercial winner and any data supporting a wider application has mysteriously 'disappeared' or put on hold by the company...or so it appears to the investment community regardless of GERN's semantics. What happened to Teferri , once a big IMET advocate...not one mention from his last Virginia beach appearance.
+ve news soon or else that gap fills @ $2.42
Shorts are everywhere creating mayhem. GERN would be $150 a share had it not been for all those rodents, smoke and mirrors.
You do realize you are creating a negative sense of un met expectations with all your mindless pumtard posting jkokao, unless of course that's your underlying agenda.